U.S. Markets open in 1 hr 36 mins

Today's Research Reports on Hemostemix, Cotinga Pharmaceuticals, Emerald Health Therapeutics and DiaMedica Therapeutics

NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Hemostemix Inc.
https://rdinvesting.com/news/?ticker=HEM.V

Cotinga Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=COT.V

Emerald Health Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=EMH.V

DiaMedica Therapeutics Inc.
https://rdinvesting.com/news/?ticker=DMA.V

Hemostemix's stock moved 7.14% lower Friday, to close the day at $0.065. The stock recorded a trading volume of 6,000 shares, which was below its three months average volume of 228,665 shares. In the last year, Hemostemix's shares have traded in a range of 0.05 - 0.16. The share price has gained 44.44% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.08 is greater than its 200-day moving average of $0.07. Shares of Hemostemix have fallen approximately 7.14 percent year-to-date.

Access RDI's Hemostemix Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HEM.V

On Friday, shares of Cotinga Pharmaceuticals recorded a trading volume of 16,700 shares, which was above the three months average volume of 15,414 shares. The stock ended the day 44.74% higher at 0.55. The share price has gained 89.66% from its 52-week low with a 52-week trading range of 0.29 - 1.88. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.49 is below its 200-day moving average of $0.63. Shares of Cotinga Pharmaceuticals have fallen approximately 60.91 percent year-to-date.

Access RDI's Cotinga Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=COT.V

Emerald Health Therapeutics' stock edged 0.38% lower Friday, to close the day at $2.59. The stock recorded a trading volume of 591,528 shares, which was below its three months average volume of 681,266 shares. In the last year, Emerald Health Therapeutics' shares have traded in a range of 1.10 - 25.06. The share price has gained 135.45% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.67 is below its 200-day moving average of $5.09. Shares of Emerald Health Therapeutics have fallen approximately 50.29 percent year-to-date.

Access RDI's Emerald Health Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EMH.V

On Friday, shares of DiaMedica Therapeutics recorded a trading volume of 633,923 shares, which was above the three months average volume of 195,846 shares. The stock ended the day 25.71% lower at 0.52. The share price has gained 147.62% from its 52-week low with a 52-week trading range of 0.21 - 0.90. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.70 is greater than its 200-day moving average of $0.49. Shares of DiaMedica Therapeutics have gained approximately 124.14 percent year-to-date.

Access RDI's DiaMedica Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=DMA.V

Our Actionable Research on Hemostemix Inc. (TSXV:HEM.V) and Cotinga Pharmaceuticals Inc. (TSXV:COT.V) and Emerald Health Therapeutics, Inc. (TSXV:EMH.V) and DiaMedica Therapeutics Inc. (TSXV:DMA.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com